APA

Kazda C. M., Ding Y., Kelly R. P., Garhyan P., Shi C., Lim C. N., Fu H., Watson D. E., Lewin A. J., Landschulz W. H., Deeg M. A., Moller D. E. & Hardy T. A. (20180108). Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. : Diabetes care.

Chicago

Kazda Christof M, Ding Ying, Kelly Ronan P, Garhyan Parag, Shi Chunxue, Lim Chay Ngee, Fu Haoda, Watson David E, Lewin Andrew J, Landschulz William H, Deeg Mark A, Moller David E and Hardy Thomas A. 20180108. Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. : Diabetes care.

Harvard

Kazda C. M., Ding Y., Kelly R. P., Garhyan P., Shi C., Lim C. N., Fu H., Watson D. E., Lewin A. J., Landschulz W. H., Deeg M. A., Moller D. E. and Hardy T. A. (20180108). Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. : Diabetes care.

MLA

Kazda Christof M, Ding Ying, Kelly Ronan P, Garhyan Parag, Shi Chunxue, Lim Chay Ngee, Fu Haoda, Watson David E, Lewin Andrew J, Landschulz William H, Deeg Mark A, Moller David E and Hardy Thomas A. Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. : Diabetes care. 20180108.